ESG Evaluation: Grifols S.A.
Grifols is a Spain-based multinational pharmaceutical company that specializes in developing, manufacturing, and marketing blood plasma-derived products and therapeutic medicines, from which it generates around 80% of its revenue. The company is the European leader and the third largest worldwide in the plasma derivative market. Grifols also supplies devices, instruments, and reagents for clinical testing laboratories. Our ESG Evaluation of 73 reflects primarily Grifols' highly traceable value chain, which allows for safety risks to be identified from donor to patient. Grifols is much less exposed to scrutiny over the affordability of its products and the access to medicines than other pharmaceutical peers, because its products are not priced at the higher end of the range. These qualities are balanced by Grifols' operation in the niche and capital-intensive plasma industry that has a larger environmental footprint than the rest of the pharmaceutical industry.Download